| Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic B Priya, S Ravi, S Kirubakaran Drug Discovery Today 28 (8), 103662, 2023 | 12 | 2023 |
| Molecular docking and molecular dynamics simulation studies of quinoline-3-carboxamide derivatives with DDR kinases–selectivity studies towards ATM kinase S Ravi, B Priya, P Dubey, V Thiruvenkatam, S Kirubakaran Chemistry 3 (2), 511-524, 2021 | 10 | 2021 |
| Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor R Bhakuni, A Shaik, B Priya, S Kirubakaran Bioorganic & Medicinal Chemistry Letters 30 (23), 127517, 2020 | 4 | 2020 |
| Exploring SPK98 for the selective sensitization of ATM-or P53-deficient cancer cells B Priya, G Dubey, S Kirubakaran ACS omega 8 (5), 4954-4962, 2023 | 2 | 2023 |
| A novel approach to investigate the combinatorial effects of TLK1 (Tousled-Like Kinase1) inhibitors with Temozolomide for glioblastoma therapy B Priya, D Chhabria, JM Dhongdi, S Kirubakaran Bioorganic Chemistry, 107643, 2024 | | 2024 |
| Temozolomide cocrystal forms with enhanced dissolution, stability and biological activity towards Glioblastoma B Priya, D Johnson, G Dubey, D Suthar, IP Kumar, V Thiruvenkatam, ... Journal of Molecular Structure, 138751, 2024 | | 2024 |
| Design and characterization of Quinoline-3-Carboxamides as selective inhibitors of ATM kinase for cancer therapeutics (Best Presentation Award) R Srimadhavi, B Priya, S Kirubakaran | | 2020 |
| Characterization of SPK 98, an ATP-competitive inhibitor of ATR and mTOR R Bhakuni, A Shaik, B Priya, S Kirubakaran | | 2019 |
